financetom
Business
financetom
/
Business
/
Major Pharma Stocks Down Amid Tariff Turmoil
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Major Pharma Stocks Down Amid Tariff Turmoil
Apr 9, 2025 7:37 AM

10:18 AM EDT, 04/09/2025 (MT Newswires) -- Major pharmaceutical stocks were down in recent Wednesday trading after multiple news outlets reported that President Donald Trump said Tuesday the US will impose a significant tariff on pharmaceutical imports.

Shares of Johnson & Johnson ( JNJ ) dropped 2.4%, Pfizer ( PFE ) slid 2.5%, Biogen (BIIB) declined 1.9%, Bristol-Myers Squibb ( BMY ) slipped 4.4%, Eli Lilly ( LLY ) lost 3%, Merck ( MRK ) retreated 2.7% and Amgen ( AMGN ) fell 2.6%.

Also on Wednesday, the Chinese Finance Ministry said China has increased tariffs on imports from the US to 84% from 34%, starting April 10, in response to Trump's decision to increase a "reciprocal tariff" on Chinese goods.

On the same day, Bloomberg reported that the European Union has adopted tariffs that will hit about 21 billion euros ($23.25 billion) worth of US goods in response to the 25% duties Trump imposed in March on the bloc's steel and aluminum exports.

Price: 146.43, Change: -3.57, Percent Change: -2.38

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Abercrombie & Fitch Co's Fiscal Q3 Adjusted Earnings, Revenue Rise; Raises Fiscal 2024 Sales Guidance
Abercrombie & Fitch Co's Fiscal Q3 Adjusted Earnings, Revenue Rise; Raises Fiscal 2024 Sales Guidance
Nov 26, 2024
07:50 AM EST, 11/26/2024 (MT Newswires) -- Abercrombie & Fitch Co ( ANF ) reported fiscal Q3 adjusted earnings Tuesday of $2.50 per diluted share, up from $1.90 a year earlier. Analysts polled by FactSet expected $2.39. Revenue for the quarter ended Nov. 2 was $1.21 billion compared with $1.06 billion a year earlier. Analysts surveyed by FactSet expected $1.19...
Amgen Says Phase 2 Study Shows MariTide Causes up to 20% Weight Loss in 1 Year
Amgen Says Phase 2 Study Shows MariTide Causes up to 20% Weight Loss in 1 Year
Nov 26, 2024
07:53 AM EST, 11/26/2024 (MT Newswires) -- Amgen ( AMGN ) said Tuesday a phase 2 study showed that its investigational obesity drug MariTide caused an up to 20% average weight loss after a year in people living with obesity or overweight without type 2 diabetes without plateauing. The study also showed that patients with type 2 diabetes achieved up...
Canada Nickel Achieves
Canada Nickel Achieves "Major Permitting Milestone" for Crawford Project in Ontario
Nov 26, 2024
07:48 AM EST, 11/26/2024 (MT Newswires) -- Canada Nickel ( CNIKF ) said Tuesday that it achieved a major permitting milestone after completing the filing of an Impact Statement for the Crawford nickel sulfide project in Ontario. Canada Nickel ( CNIKF ) said it filed the statement to the Impact Assessment Agency of Canada on Nov. 22, keeping the project...
CI Financial Deal Likely to Receive Shareholder Support, TD Says
CI Financial Deal Likely to Receive Shareholder Support, TD Says
Nov 26, 2024
07:50 AM EST, 11/26/2024 (MT Newswires) -- CI Financial Corp. ( CIXXF ) agreement to be acquired by Mubadala Capital for $32 per share will likely receive shareholder support and investors should tender to the offer, TD Securities said on Tuesday. The Toronto-based financial services company announced the transaction valued at $4.9 Billion on Monday. TD analyst Graham Ryding downgraded...
Copyright 2023-2026 - www.financetom.com All Rights Reserved